bpc 157 fragile FDA to discuss easing restrictions on peptides despite safety concerns | US healthcare Peptide Therapy for Pain Management
Description
This gives it different absorption properties and oral bioavailability , making it more accessible for non-injectable protocols
Then, it is broken down by two main enzymes, alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH)
Headache: Commonly observed at higher doses, manifesting as mild pressure, linked to vascular changes
BPC-157 is not an FDA-approved drug, which means it is not available as a retail prescription product
